Hookipa to Present at BioEquity Europe 2014

Vienna Austria, April 22, 2014 – Hookipa Biotech AG, today announced that the company's Chief
Executive Officer, Dr. Katherine Cohen, will provide an overview of the company’s technologies and
programs at the BIO Equity Europe 2014 (Amsterdam, The Netherlands, May 21-22; presentation on
Wednesday, May 21, at 5:00 p.m. CET).

About Hookipa Biotech
Hookipa Biotech AG is developing a new class of innovative prophylactic and therapeutic vaccines
based on its proprietary Vaxwave® technology. The Vaxwave® technology is a novel vaccine platform
using a replication-defective viral vector for the prevention and treatment of multiple infectious
diseases and cancer. The platform is one of the most promising new technologies for next generation
vaccines due to its ability to stimulate both potent B-cell and CD8+ T-cell immune responses.
Vaxwave® has been validated in various disease models. Unlike other vectors, Vaxwave® vaccines can
be administered repeatedly to boost the immune system. The Company is focused on the
development of its lead vaccine candidate HB101, a vaccine for immunization against
cytomegalovirus (CMV) and plans to further industrialize the Vaxwave® technology and build a
robust product pipeline in the area of infectious diseases and cancer. Hookipa has raised a total of
EUR 27 million in equity finance from internationally renowned venture capital investors including
Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures
and BioMedPartners.

Contact:
Dr. Katherine Cohen
Chief Executive Officer
Hookipa Biotech AG
Helmut-Qualtinger-Gasse 2
1030 Vienna, Austria
Email: office@hookipabiotech.com